Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Preiss

Showing results (111-120 of 160) with videos related to

Pageof 16
Sort By:
NEJM Evidence|June 21, 2024
Effect of Fenofibrate on Progression of Diabetic RetinopathyDavid Preiss, Jennifer Logue, Emily Sammons, et al.
JAMA Cardiology|August 4, 2016
Association of Lipid Fractions With Risks for Coronary Artery Disease and DiabetesJon White, Daniel I Swerdlow, David Preiss, et al.
European Journal of Heart Failure|May 22, 2012
Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)David Preiss, Dirk J van Veldhuisen, Naveed Sattar, et al.
Clinical Kidney Journal|December 8, 2018
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY studyWilliam G Herrington, David Preiss, Richard Haynes, et al.
Journal of Neurosurgery|September 24, 2005
Preoperative and postoperative mapping of cerebrovascular reactivity in moyamoya disease by using blood oxygen level-dependent magnetic resonance imagingDavid J Mikulis, Gregory Krolczyk, Hubert Desal, et al.
Clinical Kidney Journal|September 9, 2020
Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY studyWilliam G Herrington, David Preiss, Richard Haynes, et al.
Diabetes Care|February 7, 2009
Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) programDavid Preiss, Sofia Zetterstrand, John J V McMurray, et al.
Diabetologia|September 30, 2014
Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-upPaul Welsh, David Preiss, Suzanne M Lloyd, et al.
European Journal of Heart Failure|April 27, 2016
The incremental prognostic and clinical value of multiple novel biomarkers in heart failureColette E Jackson, Caroline Haig, Paul Welsh, et al.
JACC. Heart Failure|August 8, 2015
Combined Free Light Chains Are Novel Predictors of Prognosis in Heart FailureColette E Jackson, Caroline Haig, Paul Welsh, et al.
Pageof 16

Showing results (111-120 of 160) with videos related to

Sort By:
Pageof 16
NEJM Evidence|June 21, 2024
Effect of Fenofibrate on Progression of Diabetic RetinopathyDavid Preiss, Jennifer Logue, Emily Sammons, et al.
JAMA Cardiology|August 4, 2016
Association of Lipid Fractions With Risks for Coronary Artery Disease and DiabetesJon White, Daniel I Swerdlow, David Preiss, et al.
European Journal of Heart Failure|May 22, 2012
Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)David Preiss, Dirk J van Veldhuisen, Naveed Sattar, et al.
Clinical Kidney Journal|December 8, 2018
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY studyWilliam G Herrington, David Preiss, Richard Haynes, et al.
Journal of Neurosurgery|September 24, 2005
Preoperative and postoperative mapping of cerebrovascular reactivity in moyamoya disease by using blood oxygen level-dependent magnetic resonance imagingDavid J Mikulis, Gregory Krolczyk, Hubert Desal, et al.
Clinical Kidney Journal|September 9, 2020
Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY studyWilliam G Herrington, David Preiss, Richard Haynes, et al.
Diabetes Care|February 7, 2009
Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) programDavid Preiss, Sofia Zetterstrand, John J V McMurray, et al.
Diabetologia|September 30, 2014
Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-upPaul Welsh, David Preiss, Suzanne M Lloyd, et al.
European Journal of Heart Failure|April 27, 2016
The incremental prognostic and clinical value of multiple novel biomarkers in heart failureColette E Jackson, Caroline Haig, Paul Welsh, et al.
JACC. Heart Failure|August 8, 2015
Combined Free Light Chains Are Novel Predictors of Prognosis in Heart FailureColette E Jackson, Caroline Haig, Paul Welsh, et al.
Pageof 16